



PURGED *RAK*

Food and Drug Administration
Minneapolis District
240 Hennepin Avenue
Minneapolis MN 55401-1999
Telephone: 612-334-4100

November 3, 2000

WARNING LETTER

CERTIFIED MAIL
RETURN RECEIPT REQUESTED

Refer to MIN 01 - 09

Dennis Doran
Administrator
Cambridge Medical Center
701 S. Dellwood Street
Cambridge, Minnesota 55008

Dear Mr. Doran:

On October 18, 2000, a representative of the State of Minnesota, acting on behalf of the Food and Drug Administration (FDA) inspected your facility (FDA Certificate #169714). This inspection revealed a serious regulatory problem involving the mammography at your facility.

Under a United States Federal law, the Mammography Quality Standards Act of 1992 (MQSA), your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. Based on the documentation your site presented at the time of the inspection, the following Level 2 findings were documented at your facility:

Repeat Level 2 Non-Compliance:

1. A radiological technologist did not meet the continuing education requirement of having completed a minimum of 15 CEUs in mammography in the 36-month period preceding the inspection.


During the current inspection *wavy line* presented documentation of only six CEUs for the evaluation period. During the previous (1999) inspection, a different technologist was cited for not meeting the continuing education requirement.

Page Two

Dennis Doran
November 3, 2000

Individuals failing to meet either the "Initial" or "Continuing" MQSA requirements must immediately cease performing mammography independently. Requirements for re-qualification are listed in the Final regulation that became effective on April 28, 1999. Conditions for Direct Supervision of unqualified personnel are specified in regulation and formal FDA policy. Policy references may be found at the Internet address below.

Level 2 Non-Compliance:

2. Mammograms were processed in your film processor () located in the darkroom when it was out of control limits on three days. Regulations require that the processor must be brought back into control before processing clinical images through it.

The specific problems noted above appeared on your MQSA Facility Inspection Report which was issued to your facility following the close of the inspection.

Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within 15 working days from the date you received this letter:

- The specific steps you have taken to correct all of the violations noted in this letter;
- Each step your facility is taking to prevent the recurrence of similar violations;
- Equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- Sample records that demonstrate proper record keeping procedures if the findings relate to quality control or other records.

Please submit your response to Thomas W. Garvin, Radiological Health Specialist, Food and Drug Administration, 2675 N. Mayfair Road, Suite 200, Milwaukee, WI 53226-1305.


Page Three

Dennis Doran
November 3, 2000

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov/cdrh/mammography/index.html>.

If you have specific questions about mammography facility requirements or about the content of this letter please feel free to phone Mr. Garvin at (414)771-7167 ext. 12.

Sincerely,



James A. Rahto
Director
Minneapolis District

TWG/ccl

BY

xc:

[Handwritten signature]
Lead Interpreting Radiologist
Cambridge Medical Center
701 S. Dellwood Street
Cambridge, MN 55008

Sue McClanahan
Supervisor, Section of Radiation Control
Minnesota Department of Health
P.O. Box 64975
St. Paul, MN 55164-0975

Priscilla F. Butler
Director, Breast Imaging Accreditation Programs
American College of Radiology
1891 Preston White Drive
Reston, VA 20191